BR112022015447A2 - Métodos para o tratamento de escleroderma e condições relacionadas - Google Patents

Métodos para o tratamento de escleroderma e condições relacionadas

Info

Publication number
BR112022015447A2
BR112022015447A2 BR112022015447A BR112022015447A BR112022015447A2 BR 112022015447 A2 BR112022015447 A2 BR 112022015447A2 BR 112022015447 A BR112022015447 A BR 112022015447A BR 112022015447 A BR112022015447 A BR 112022015447A BR 112022015447 A2 BR112022015447 A2 BR 112022015447A2
Authority
BR
Brazil
Prior art keywords
scleroderma
methods
treatment
related conditions
igf
Prior art date
Application number
BR112022015447A
Other languages
English (en)
Portuguese (pt)
Inventor
Thompson Elizabeth
Ramanathan Srini
Original Assignee
Horizon Therapeutics Ireland Dac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland Dac filed Critical Horizon Therapeutics Ireland Dac
Publication of BR112022015447A2 publication Critical patent/BR112022015447A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022015447A 2020-02-04 2021-02-04 Métodos para o tratamento de escleroderma e condições relacionadas BR112022015447A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970063P 2020-02-04 2020-02-04
US202063049522P 2020-07-08 2020-07-08
PCT/US2021/016666 WO2021158823A1 (en) 2020-02-04 2021-02-04 Methods for the treatment of scleroderma and related conditions

Publications (1)

Publication Number Publication Date
BR112022015447A2 true BR112022015447A2 (pt) 2022-11-16

Family

ID=77200418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015447A BR112022015447A2 (pt) 2020-02-04 2021-02-04 Métodos para o tratamento de escleroderma e condições relacionadas

Country Status (11)

Country Link
US (2) US20210253686A1 (enExample)
EP (1) EP4100127A4 (enExample)
JP (1) JP2023515771A (enExample)
KR (1) KR20220151619A (enExample)
CN (1) CN115397518A (enExample)
AU (1) AU2021217378A1 (enExample)
BR (1) BR112022015447A2 (enExample)
CA (1) CA3169994A1 (enExample)
IL (1) IL295372A (enExample)
MX (1) MX2022009628A (enExample)
WO (1) WO2021158823A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025519600A (ja) * 2022-06-10 2025-06-26 アセリリン， インコーポレイテッド 抗ｉｇｆ－１ｒ抗体組成物
KR20250048156A (ko) * 2022-06-29 2025-04-07 리룸 테라퓨틱스, 인크. 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료
WO2025007015A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for multiple sclerosis
WO2025007012A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for rheumatoid arthritis
CN119548621A (zh) * 2023-09-01 2025-03-04 苏州普乐康医药科技有限公司 抗igf-1r抗体或其抗原结合部分在减重中的应用
WO2025155894A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596854A4 (en) * 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
JP2012505900A (ja) * 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
EP2785382B1 (en) * 2011-12-02 2019-01-02 IBC Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
EP2647994A1 (en) * 2012-04-03 2013-10-09 Universitätsklinikum Freiburg Method for diagnosis of pulmonary involvement in systemic sclerosis
CN107982247A (zh) * 2018-01-23 2018-05-04 中日友好医院 二甲双胍在制备治疗肺纤维化药物中的应用
EP3752161A4 (en) * 2018-02-15 2021-12-22 Children's Hospital Medical Center METHOD OF TREATMENT OF FIBROSE

Also Published As

Publication number Publication date
KR20220151619A (ko) 2022-11-15
EP4100127A4 (en) 2024-02-28
IL295372A (en) 2022-10-01
EP4100127A1 (en) 2022-12-14
US20210253686A1 (en) 2021-08-19
MX2022009628A (es) 2022-11-07
US20240279323A1 (en) 2024-08-22
WO2021158823A1 (en) 2021-08-12
CN115397518A (zh) 2022-11-25
AU2021217378A1 (en) 2022-09-01
CA3169994A1 (en) 2021-08-12
JP2023515771A (ja) 2023-04-14

Similar Documents

Publication Publication Date Title
CL2025000105A1 (es) Compuestos inhibidores de la ras y uso para tratar cáncer.
MX2022009628A (es) Métodos para el tratamiento de la esclerodermia y padecimientos relacionados.
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
DOP2023000041A (es) Compuestos y métodos para el tratamiento de infecciones virales
BR112021012812A2 (pt) Csf1r inhibitors para uso e tratamento de câncer
CL2020002809A1 (es) Construcciones para terapia génica y métodos para su uso
BR112021008873A8 (pt) Formulação
BR112019023898A2 (pt) método para tratamento de câncer gástrico, uso de um anticorpo e composição
CO2022017690A2 (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
CL2023003518A1 (es) Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina
MX2025003354A (es) Anticuerpos que se unen a 5t4
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112022001329A2 (pt) Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CY1125536T1 (el) Συνθεσεις για τη θεραπεια της αμυλοειδωσης
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
UY27499A1 (es) Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular
BR112022002029A2 (pt) Uso de sepiapterina e seus metabólitos para tratar exposição à radiação
BR112022007216A2 (pt) Métodos para tratamento de linfoma difuso, kit e imunoconjugado
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112022018586A2 (pt) Derivados de ácido borônico e usos terapêuticos dos mesmos
BR112022008655A2 (pt) Composições de copolímero em bloco responsivas ao ph, micelas, e métodos de uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.